Covid 19 Research using Clinical Trials (Home Page)
Questionnaire by phone callWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug148 | COVID 19 diagnostic test by PCR Wiki | 1.00 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012859 | Sjogren's Syndrome NIH | 1.00 |
| D015535 | Arthritis, Psoriatic NIH | 0.71 |
| D001327 | Autoimmune Diseases NIH | 0.71 |
| D001168 | Arthritis NIH | 0.58 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.58 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
NCT04345159 SARS-CoV-2 Systemic Lupus Erythematosus Rheumatoid Arthritis Sjogren's Syndrome Psoriatic Arthritis Other: Questionnaire by phone call MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusion
Related HPO nodes (Using clinical trials)
HP:0001369: Arthritis
Genes 263
COL5A2 HPGD COL1A1 CANT1 HJV TRPV4 CCR1 HNF1B PTPN2 LACC1 BTK TFR2 HOXD10 CLCN7 COL9A2 PTPN22 MMP2 NLRP3 STAT4 GHR RNF168 TREX1 COL9A3 PADI4 SLC40A1 WIPF1 COL2A1 MMP14 RASGRP1 PRKCD SEC61A1 SLC37A4 COL2A1 HNF1B TBX1 PTPN22 STAT4 MEFV AEBP1 COL2A1 IL2RB HLA-DRB1 HGD PSTPIP1 ANKRD55 FBN1 GBA HPGD CCN6 ANKRD55 FGFR3 NOD2 ACAN COMP HPRT1 AGA IRF5 NLRC4 MUC1 IL12B GNAS HPGD MATN3 CASP10 ASAH1 COMP MYH14 HIRA SLCO2A1 SLC22A4 HLA-B FRZB CD244 PRG4 COL11A2 LMX1B TNFRSF1A ACAN TGFB3 STAT4 COL11A1 IL10 MEFV LRP6 RAG2 IFIH1 TRAPPC2 LBR IL10 COL5A1 IGHM LEMD3 HLA-DRB1 DNASE1 COMP SH3KBP1 NFKBIL1 IL12A-AS1 IL12A ARVCF COL2A1 CLCN7 IL23R KIF7 DNASE1L3 SEC24C IL6 FCGR2A COL9A3 SLC37A4 AIP SPTB HPRT1 GDF5 COL2A1 JMJD1C TCF3 IL2RB COMP HLA-B TRAPPC2 COL5A1 HNF4A F9 COMT UFD1 SMAD3 STAT3 HPRT1 HGD SPTA1 GJB6 ATP7B COL9A1 F8 BLNK PTPN22 APOE UMOD TREX1 MMP13 ZNF687 NLRP3 GJB2 PSMB9 PTPN22 TF CD79B COL2A1 MMP13 LMNA UFSP2 ERAP1 LRBA COPA CCR6 COL9A2 ABCG8 TRPS1 CD247 MIF C1R GP1BB PFKM LRRC8A FAS PHEX UMOD ANKH G6PC FCGR2B COL2A1 CCN6 IGLL1 CAV1 PSTPIP1 NLRP12 KIF22 ANKH SPP1 ATP7B CTLA4 CD79A SLC4A1 RNASEH2B EPCAM FAS NLRP3 CCN2 WAS COL1A1 PSMB4 UFSP2 TLR4 STAT4 MVK ACP5 MATN3 HPRT1 SLC12A3 BTK MTHFD1 ADA2 RAG1 PIK3R1 SCARB2 OCRL ADAR HLA-DRB1 RREB1 COL11A2 RNASEH2C PTPN22 GPR101 IL36RN CIITA C1QA SLC26A2 NLRP3 PHEX RNASEH2A KLRC4 COL2A1 ZMPSTE24 CD247 CFI UBAC2 BTK HLA-B DNAJB11 GCH1 FAS C4A COL11A2 EPB42 PRPS1 IRAK1 EXT2 MEFV MEFV GLA ACAN FASLG MVK MATN3 CLCNKB IL2RA EXT1 ASPN COL3A1 IL2RA TBX1 COL9A1 NOD2 HLA-C COL2A1 ANK1 TRPV4 SAMHD1 PTPN2 SMAD3 MLX DCLRE1C HP:0002960: Autoimmunity
Genes 223
DDX41 PTPN2 LACC1 MS4A1 FASLG LIG4 NFKB2 CASP10 STAT4 TCIRG1 POU2AF1 STOX1 TREX1 RFX5 WIPF1 RASGRP1 ITPR3 PRKCD C1GALT1C1 TNFRSF13B SERPING1 TBX1 PTPN22 STAT4 PEPD IL2RB POLG HLA-DRB1 GFI1 NBN ANKRD55 PTPN22 ANKRD55 TNFSF15 ICOS RFXANK TNFSF12 IFNGR1 C3 HLA-DQB1 FAS ITCH TNFAIP3 NRAS RFXAP TTC7A IL2RB IRF5 GPR35 SERPING1 STAT1 HLA-DPA1 CASP10 HLA-DRB1 SLC7A7 HIRA TNFRSF13B KDM6A SERPING1 CD3G DNASE1L3 ADA KMT2D SMPD1 CIITA HLA-DPB1 STAT4 LCK PRSS1 ICOS ITK IFIH1 CTLA4 PLCG2 HLA-DRB1 DNASE1 C1QC CSF2RA RAG1 CCR6 SPIB ARVCF RAG2 GALC TNFRSF13C ITCH DNASE1L3 MST1 SEC24C IL6 FCGR2A IL2RG PNP CR2 ADA JMJD1C MASP2 IL12RB1 IL2RB MMEL1 ZAP70 COMT UFD1 NBN STAT3 TNPO3 KRAS CD19 TREX1 TBX2 RAG1 AIRE HLA-DRB1 CORIN PTPN22 LMNB2 C1QB RAG1 TRAC SRP54 NHEJ1 FOXP3 TPP2 LRBA CCR6 HAVCR2 MMP2 FOXD3 CD247 TNFRSF13B MIF C1R GP1BB HNF1A DCLRE1C FAS ICOS CTLA4 CAV1 IL7R IRF5 CSF2RB TTC7A FCGR2B CAV1 SPP1 TNFRSF13C CTLA4 FADD CTLA4 IL7R C8A C1R ARHGEF1 RNASEH2B CD19 CR2 STAT1 FOXP3 CCN2 WAS IL2RA IL6 PTPN22 ADA2 PRKCD CCN2 ACP5 C2 SLC12A3 CFTR MTHFD1 C4A ADA2 PGM3 CHD7 KIAA0319L ADAR RREB1 RNASEH2C PTPN22 C1QA TCF4 IL12A RNASEH2A CD247 BTK FCGR2C ADA2 FAS C1QA CD81 PAX4 RAG2 C1S IRAK1 PRKCD ELANE TREX1 NFKB1 ZAP70 SEC23B NLRP1 PTEN TNFSF12 FLT1 ADA FASLG PIK3R1 STIM1 IRF5 CLCNKB IL2RA CTRC PRTN3 IL2RA TBX1 RMRP SPINK1 SAMHD1 PTPN2 NFKB2 DCLRE1C SNP 0
Primary Outcomes
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusion